MPE Newsletter | COVID-19 vaccination for myeloma patients


The SARS-CoV-2 (COVID-19) pandemic has raised a lot of questions, especially around vaccination. Myeloma Patients Europe (MPE) is working to respond some of the most frequently asked questions about the current approved vaccines in Europe and how they affect myeloma and AL amyloidosis patients.
MPE has developed the Q&A “SARS-CoV-2 (COVID-19) Vaccination for Myeloma Patients” to cover the following topics:
  • The approved vaccines in Europe as of March 2021.
  • How the approved vaccines work and how they are administered.
  • The side effects and efficacy of the approved vaccines.

MPE is committed to developing useful informational materials and resources for members and patients on COVID-19 ( If you feel there is a need for these materials to be translated into your language, please email the MPE Communications Manager, Ana Vallejo, at

MPE COVID-19 Video Series:

As part of the information developed around the COVID-19 vaccine for myeloma patients, Myeloma Patients Europe (MPE) recently interviewed Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany. Watch this video here.

Watch here the MPE COVID-19 Video Series.



Copyright © 2021 Myeloma Patients Europe, All rights reserved.


Zagreb, HR
slaba kiša

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
Web adresa:
IBAN: HR 36 2340 0091 1100 4711 4

Važni datumi


Health through Knowledge

Klasa optimist

Istaknuti sponzori HULL-a